Evidence map›Paper›PMID 41120961›Full record

ArticleBMC infectious diseases2025

Clinical burden and biochemical profiles of viral hepatitis in a tertiary healthcare facility in North Central, Nigeria.

Legbel Ikenna Uguru, Adamu Ishaku Akyala, Yakubu Boyi Ngwai, Daniel Ikenna Uguru, Stephen Olaide Aremu

Abstract read
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Legbel Ikenna UguruGlobal Health and Infectious Diseases Control Institute, Nasarawa State University, Keffi, Nasarawa State, Nigeria.
Adamu Ishaku AkyalaGlobal Health and Infectious Diseases Control Institute, Nasarawa State University, Keffi, Nasarawa State, Nigeria.ORCID http://orcid.org/0000-0002-4168-6104
Yakubu Boyi NgwaiGlobal Health and Infectious Diseases Control Institute, Nasarawa State University, Keffi, Nasarawa State, Nigeria.ORCID http://orcid.org/0000-0002-8207-9167
Daniel Ikenna UguruFederal Medical Center, Keffi, Nasarawa State, Nigeria.
Stephen Olaide AremuGlobal Health and Infectious Diseases Control Institute, Nasarawa State University, Keffi, Nasarawa State, Nigeria. dr.aresteph@gmail.com.ORCID http://orcid.org/0000-0002-7473-7254

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionViral hepatitis remains a significant global health concern, with hepatitis B virus (HBV) and hepatitis C virus (HCV) contributing substantially to chronic liver disease, cirrhosis, and hepatocellular carcinoma. In sub-Saharan Africa, the public health burden of hepatitis is exacerbated by late diagnosis, inadequate monitoring, and limited resources. This study aimed to evaluate liver enzyme levels and their association with demographic factors and clinical severity among hepatitis patients in a tertiary health facility in Nigeria to inform targeted interventions. METHODOLOGY: A retrospective chart study was conducted involving 723 hepatitis patients at Federal Medical Center Keffi, Nigeria. Sociodemographic data were collected alongside laboratory results for alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin. Patients were classified as having HBV, HCV, or HBV/HCV co-infection. Data analysis included descriptive statistics, ANOVA, correlation, and multiple regression models. RESULTS AND DISCUSSION: The majority of patients were aged 18-50 years with three levels (70.1%), with a slight male predominance (54%). Hepatitis B was the most common infection (65%), followed by HCV (23%) and co-infection (12%). Co-infected patients showed the highest mean levels of liver enzymes and total bilirubin (ALT: 210 IU/L, AST: 195 IU/L, ALP: 320 IU/L, bilirubin: 5.5 mmol/L). Clinical severity was positively correlated with all liver markers (r = 0.54-0.65, p < 0.01), and multiple regression analysis confirmed that co-infection and severity of symptoms associated with Hepatitis B were the strongest predictors of elevated liver enzymes. These findings align with global evidence that co-infection accelerates liver damage, and emphasize the need for sex- and age-sensitive screening and early treatment programs.

conclusionThis study highlights the biochemical and demographic characteristics of hepatitis patients in Nigeria, emphasizing the heightened disease severity in co-infected individuals. Integration of liver enzyme monitoring with demographic profiling can improve early diagnosis and resource allocation in hepatitis management. Strengthening public health infrastructure and implementing routine fibrosis assessment are vital to reducing hepatitis-related morbidity in resource-limited settings.

Indexed as

CoinfectionCost of IllnessHepatitis BHepatitis CAdolescentAdultAge FactorsAlanine TransaminaseAlkaline PhosphataseAspartate AminotransferasesBilirubinFemaleHumansLiverMaleMiddle AgedAlanine TransaminaseAlkaline PhosphataseAspartate AminotransferasesBilirubinCo-infectionDisease severityLiver enzymesNigeriaPublic healthViral hepatitis

Identifiers

PMID41120961
PMCPMC12539178

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.